news
INO-4800 COVID-19 vaccine provides cross-reactive immune responses against variants
Antibodies induced by the investigational DNA vaccine candidate, INO-4800, were found to be able to neutralise three SARS-CoV-2 emerging variants of concern.
List view / Grid view
Inovio Pharmaceuticals
news
Patient dosed with first Lassa fever vaccine to reach human trials
The first trial participant has been given INO-4500 in Ghana - INO-4500 is a DNA vaccine candidate being developed to protect against Lassa fever.
article
COVID-19 and big pharma: what are 15 leading companies doing to develop a coronavirus vaccine?
A new report has revealed the vaccine R&D efforts of 15 of the leading pharmaceutical companies to combat the COVID-19 coronavirus.
article
Potential COVID-19 therapeutics currently in development
As the world rushes to identify the best coronavirus treatments and vaccines, John Cahill rounds up the latest developments in potential COVID-19 therapies.
news
CEPI announces three programmes to develop coronavirus vaccine
The CEPI has announced three respective projects with Inovio, the University of Queensland and Moderna, to develop a vaccine for the novel coronavirus, nCoV-2019.
news
Approval for first-in-human Zika vaccine trial to go ahead
20 June 2016 | By Victoria White, Digital Content Producer
Inovio and GeneOne Life Science have received approval to initiate a Phase I human trial to evaluate Inovio’s Zika DNA vaccine (GLS-5700)...
news
Inovio’s Ebola vaccine generates robust immune responses in humans
30 March 2016 | By Victoria White
Inovio’s Ebola vaccine, INO-4212, was safe, tolerable, and generated strong T cell and antibody responses in its Phase I study of 75 healthy subjects...
news
Patient recruitment starts for MERS vaccine trial
28 January 2016 | By Victoria White
Inovio and GeneOne Life Science are co-developing Inovio’s MERS vaccine (GLS-5300) in partnership with the Walter Reed Army Institute of Research...
news
INO-3112 shows robust responses in head and neck cancer
6 November 2015 | By Victoria White
Immunology results show that INO-3112 generated robust HPV16/18 specific CD8+ T cell responses and antibodies against HPV16/18...
news
Successful Phase 2b trial results of HPV immunotherapy VGX-3100 announced
Results from Inovio’s Phase 2b trial with VGX-3100 in treating women with high grade cervical neoplasia have been published.
news
First patient dosed in Phase I trial of universal HIV vaccine Pennvax-GP
8 September 2015 | By Victoria White
The trial will measure immune responses following administration of Pennvax-GP in four groups of healthy subjects receiving the vaccine with and without an immune activator (IL-12)...
news
Medimmune and Inovio Pharmaceuticals agree to DNA-based immunotherapy collaboration
11 August 2015 | By Katie Sadler, Digital Content Producer, European Pharmaceutical Review
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a license agreement and collaboration with Inovio Pharmaceuticals, a biotechnology company developing DNA-based immunotherapies for cancer and infectious diseases.
news
Inovio initiates Phase I trial of its Ebola DNA immunotherapy
12 May 2015 | By Victoria White
Inovio Pharmaceuticals has initiated a Phase I trial to evaluate safety, tolerability and immune responses of its Ebola DNA immunotherapy...
